Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Annals of Oncology : Official Journal of the European Society for Medical Oncology
P S GrimisonAustralian and New Zealand Urogenital and Prostate Cancer Trials Group

Abstract

This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerability and activity of accelerated bleomycin, etoposide and cisplatin (BEP) as first-line chemotherapy for metastatic germ cell tumours. Patients were planned to receive cisplatin 20 mg/m(2) and etoposide 100 mg/m(2) days 1-5, and pegfilgrastim 6 mg day 6, all repeated every 2 weeks for four cycles (three cycles for good prognosis). Bleomycin was given at 30 000 IU weekly to a total of 12 doses (9 doses for good prognosis). Primary end point was feasibility, defined as the proportion of patients able to complete the etoposide and cisplatin components of BEP and be eligible to receive a fourth cycle of BEP by day 50. Twelve poor, 16 intermediate and 15 good prognosis (n = 43) eligible patients were enrolled. Two patients aged >40 years were ineligible and excluded from analyses. The regimen was feasible in 86%, not feasible in 7% and not assessable in 7% of patients. Most common grade 3/4 adverse events were non-neutropenic infection (16%) and febrile neutropenia (12%). Complete response (CR) to chemotherapy and surgery was achieved in 33% poor-prognosis, 81% intermediate-prognosis and 100% good-prognosis patients. At median follow-up of 27 mont...Continue Reading

References

Aug 15, 2001·Chest·S Sleijfer
Aug 19, 2003·Pharmacotherapy·William C Zamboni
Dec 17, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E A CalhounD Cella
Jun 4, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S A Gregory, L Trümper
Jun 21, 2005·Nature Reviews. Cancer·John J Kim, Ian F Tannock
Jul 16, 2010·Journal of the National Cancer Institute·Peter S GrimisonGuy C Toner
Nov 26, 2010·Journal of the National Cancer Institute·Luisa BonillaSalomon M Stemmer
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald de WitLaurence Collette
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard B WomerAaron R Weiss

❮ Previous
Next ❯

Citations

Jan 1, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·I N OlverUNKNOWN Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Oct 22, 2015·Expert Opinion on Biological Therapy·Matteo LambertiniPaolo Pronzato
Oct 14, 2014·Urologic Oncology·Brent O'Carrigan, Peter Grimison
Jun 22, 2015·Urologic Oncology·Tanya B DorffDavid I Quinn
Jun 16, 2016·Internal Medicine Journal·F T RoncolatoUNKNOWN Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP)
Oct 16, 2016·International Journal of Radiation Oncology, Biology, Physics·Zeinab Abou YehiaBouthaina S Dabaja
Mar 5, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Brittney M ShippeeKristy L Richards
Nov 19, 2017·Molecular Cancer·Ruobing JiaXianqun Fan
Jul 7, 2018·Current Opinion in Urology·Costantine Albany
Oct 7, 2018·Der Anaesthesist·J C Schäuble, T Heidegger
Jul 4, 2020·ANZ Journal of Surgery·King Tung CheungShomik Sengupta
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas A OlsonA Lindsay Frazier
Aug 14, 2019·Journal of Oncology Practice·Adriana FonsecaFurqan Shaikh
Feb 3, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fay H CaffertyUNKNOWN TE23 Trial Management Group and Collaborators
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Alan Horwich

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.